173 related articles for article (PubMed ID: 11271340)
1. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
Mor E; Patel T; Glabman S; Sheiner P; Emre S; Guy S; Schwartz M; Miller C
Transpl Int; 1994; 7 Suppl 1():S77-80. PubMed ID: 11271340
[TBL] [Abstract][Full Text] [Related]
2. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation.
McDiarmid SV; Colonna JO; Shaked A; Ament ME; Busuttil RW
Transplantation; 1993 Oct; 56(4):847-53. PubMed ID: 7692636
[TBL] [Abstract][Full Text] [Related]
3. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors.
Niel OR; Berthoux F; Albano L; Dahan P; Aoudia R; Gugenheim J; Cassuto E
Transplant Proc; 2009 Oct; 41(8):3329-32. PubMed ID: 19857743
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
Platz KP; Mueller AR; Blumhardt G; Bachmann S; Bechstein WO; Kahl A; Neuhaus P
Transpl Int; 1994; 7 Suppl 1():S52-7. PubMed ID: 11271297
[TBL] [Abstract][Full Text] [Related]
5. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
Radermacher J; Meiners M; Bramlage C; Kliem V; Behrend M; Schlitt HJ; Pichlmayr R; Koch KM; Brunkhorst R
Transpl Int; 1998; 11(1):3-10. PubMed ID: 9503547
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Richards TM; Crotty PH; Beaver SJ; Steers JL; Wiesner RH
Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
[TBL] [Abstract][Full Text] [Related]
7. Renal function after 10 years' treatment with cyclosporin for psoriasis.
Powles AV; Hardman CM; Porter WM; Cook T; Hulme B; Fry L
Br J Dermatol; 1998 Mar; 138(3):443-9. PubMed ID: 9580797
[TBL] [Abstract][Full Text] [Related]
8. Importance of allograft biopsy in renal transplant recipients: correlation between clinical and histological diagnosis.
Al-Awwa IA; Hariharan S; First MR
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S15-8. PubMed ID: 9631859
[TBL] [Abstract][Full Text] [Related]
9. Renal function in pediatric liver transplant patients.
McDiarmid SV
Kidney Int Suppl; 1996 Jan; 53():S77-84. PubMed ID: 8770996
[TBL] [Abstract][Full Text] [Related]
10. Steroid withdrawal 3 months after liver transplantation--does FK 506 confer any advantage over cyclosporin?
Dmitrewski J; Ayres S; Gunson BK; Buist LJ; Buckels JA; McMaster P; Mayer AD
Transpl Int; 1994; 7 Suppl 1():S85-7. PubMed ID: 11271342
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation.
Tauxe WN; Mochizuki T; McCauley J; Starzl TE; Jain A; Charron M
Transplant Proc; 1991 Dec; 23(6):3146-7. PubMed ID: 1721386
[TBL] [Abstract][Full Text] [Related]
12. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
[TBL] [Abstract][Full Text] [Related]
13. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.
Tinawi M; Miller L; Bastani B
Clin Transplant; 1997 Feb; 11(1):1-8. PubMed ID: 9067686
[TBL] [Abstract][Full Text] [Related]
14. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients.
Assan R; Blanchet F; Feutren G; Timsit J; Larger E; Boitard C; Amiel C; Bach JF
Diabetes Metab Res Rev; 2002; 18(6):464-72. PubMed ID: 12469360
[TBL] [Abstract][Full Text] [Related]
15. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients.
Devlin J; Williams R; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Bismuth H; Groth C
Transpl Int; 1994; 7 Suppl 1():S22-6. PubMed ID: 11271207
[TBL] [Abstract][Full Text] [Related]
16. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.
Pham SM; Kormos RL; Hattler BG; Kawai A; Tsamandas AC; Demetris AJ; Murali S; Fricker FJ; Chang HC; Jain AB; Starzl TE; Hardesty RL; Griffith BP
J Thorac Cardiovasc Surg; 1996 Apr; 111(4):764-72. PubMed ID: 8614136
[TBL] [Abstract][Full Text] [Related]
17. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study.
Ericzon B; Groth C; Bismuth H; Calne R; McMaster P; Neuhaus P; Otto G; Pichlmayr R; Williams R
Transpl Int; 1994; 7 Suppl 1():S11-4. PubMed ID: 11271178
[TBL] [Abstract][Full Text] [Related]
18. High incidence of severe infections in heart transplant recipients receiving tacrolimus.
Peraira JR; Segovia J; Arroyo R; Ortiz P; Fuertes B; Moñivas V; Burgos R; Alonso-Pulpón L
Transplant Proc; 2003 Aug; 35(5):1999-2000. PubMed ID: 12962875
[TBL] [Abstract][Full Text] [Related]
19. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
[TBL] [Abstract][Full Text] [Related]
20. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
